Researchers at Trinity College Dublin, working with the biotech firm Breye Therapeutics, have reported early findings that an oral medication called danegaptide may protect against vision-threatening damage in nonproliferative diabetic retinopathy (NPDR). The condition is a common complication of diabetes and a leading cause of blindness in working-age adults.
The study, described as preliminary, suggests that a simple pill could offer a convenient way to prevent the retinal damage that characterizes NPDR. Unlike more invasive treatments, which often require injections or laser procedures, danegaptide is taken orally, potentially making early intervention far easier for patients.
Because the findings are early, the researchers caution that more work is needed before the drug could become a standard therapy. The source article does not include details on trial size or long-term outcomes, so the results should be interpreted as promising but not conclusive.